AbbVie, Elahere

AbbVie’s Elahere wins European approval for certain ovarian cancers
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab ...
AbbVie receives EC approval of Elahere
AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive,
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
AbbVie on Monday said the green light covers Elahere for treating adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult
pharmaphorum3h
AbbVie bags EU nod for key drug from ImmunoGen takeover
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Hosted on MSN7mon
Elahere secures full approval from FDA for types of ovarian cancer
AbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug Administration (FDA) for the treatment of certain types of ovarian cancer.
The Globe and Mail6d
Is This Dividend King a Buy After a Strong Q3 Report?
In the first quarter, AbbVie acquired ImmunoGen and its flagship cancer therapy, ELAHERE. This acquisition will allow ...
pharmaphorum4d
ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer
ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...
Hosted on MSN1mon
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
If approved, this will be the first regulatory approval for Elahere in the EU. ABBV Stock Performance Year to date, AbbVie’s shares have moved up 24.9% compared with the industry’s 23.5% rise.